Cargando…
A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53
Mutations in TP53 occur commonly in the majority of human tumors and confer aggressive tumor phenotypes, including metastasis and therapy resistance. CB002 and structural-analogs restore p53 signaling in tumors with mutant-p53 but we find that unlike other xanthines such as caffeine, pentoxifylline,...
Autores principales: | Hernandez Borrero, Liz, Dicker, David T, Santiago, John, Sanders, Jennifer, Tian, Xiaobing, Ahsan, Nagib, Lev, Avital, Zhou, Lanlan, El-Deiry, Wafik S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321552/ https://www.ncbi.nlm.nih.gov/pubmed/34324416 http://dx.doi.org/10.7554/eLife.70429 |
Ejemplares similares
-
P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9
por: Tian, Xiaobing, et al.
Publicado: (2021) -
Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
por: Zhang, Shengliang, et al.
Publicado: (2022) -
Targeting Mutated p53: Naivete and Enthusiasm to Attempt the Impossible
por: El-Deiry, Wafik S.
Publicado: (2023) -
The role of p53 in anti-tumor immunity and response to immunotherapy
por: Carlsen, Lindsey, et al.
Publicado: (2023) -
Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents
por: Carlsen, Lindsey, et al.
Publicado: (2021)